Inhibition of gastric inhibitory polypeptide signaling prevents obesity
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Secretion of gastric inhibitory polypeptide (GIP), a duodenal hormone, is primarily induced by absorption of ingested fat. Here we describe a novel pathway of obesity promotion via GIP. Wild-type mice fed a high-fat diet exhibited both hypersecretion of GIP and extreme visceral and subcutaneous fat deposition with insulin resistance. In contrast, mice lacking the GIP receptor (Gipr(-/-)) fed a high-fat diet were clearly protected from both the obesity and the insulin resistance. Moreover, double-homozygous mice (Gipr(-/-), Lep(ob)/Lep(ob)) generated by crossbreeding Gipr(-/-) and obese ob/ob (Lep(ob)/Lep(ob)) mice gained less weight and had lower adiposity than Lep(ob)/Lep(ob) mice. The Gipr(-/-) mice had a lower respiratory quotient and used fat as the preferred energy substrate, and were thus resistant to obesity. Therefore, GIP directly links overnutrition to obesity and it is a potential target for anti-obesity drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“tirzepatide proved superior in improving glycemic control relative to treatment with semaglutide (1 mg)133, insulin degludec134, insulin glargine135,136, and insulin lispro137; importantly, with preserved efficacy and without compromising safety in subjects at risk for cardiovascular diseases136.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“Despite the slight differences based on the subject cohort and the duration of treatment, this magnitude of weight loss was largely consistent with the SURPASS trials132-140.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“Combined, the SURPASS and SURMOUNT trials have verified the safety of tirzepatide to be consistent with GLP-1R agonists, along with its enhanced efficacy at maximal doses of 5, 10 and 15 mg (Table 1)132-136,143,145-147”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“While GIPR antagonism has been shown to reduce adiposity in preclinical models [64], the clinical data show tirzepatide, a dual GLP-1R/GIPR agonist, produces greater weight loss and glucose lowering than the GLP-1R agonist semaglutide alone [42], particularly at doses which comparably engage the GLP-1R [61].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [64]
In the citing paper
“Initial reports that GIPR null mice [64] are protected from diet-induced obesity have been supported by preclinical studies in rodents and non-human primates that GIPR antagonism induces additive weight loss when combined with GLP-1R agonism [32,67], and human genetics data that loss-of-function GIPR variants associate with reduced adiposity [68].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [64]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419 · cited 1×
“Obese Lep ob / Lep ob mice exhibit a marked increase in adipose tissue due to hyperphagia caused by mutation of the leptin gen”
BackgroundSerum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans
Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W., Nyce, M. R., Ohannesian, J. P., Marco, C. C., McKee, L. J., Bauer, T. L., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340503 · Cited by 6,326
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Weight-Reducing Effects of the Plasma Protein Encoded by the obese Gene
Halaas, J. L., Gajiwala, K. S., Maffei, M., Cohen, S. L., Chait, B. T., Rabinowitz, D., Lallone, R. L., Burley, S. K., & Friedman, J. M. (1995) · Science · doi:10.1126/science.7624777 · Cited by 4,451
Obesity and insulin resistance
Kahn, B. B., & Flier, J. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10842 · Cited by 3,225
Obesity and the regulation of energy balance
Spiegelman, B. M., & Flier, J. S. (2001) · Cell · doi:10.1016/s0092-8674(01)00240-9 · Cited by 2,398
Frederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
Green, H., & Kehinde, O. (1975) · Cell · doi:10.1016/0092-8674(75)90087-2 · Cited by 1,360
Dietary fat intake does affect obesity!
Bray, G. A., & Popkin, B. M. (1998) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.6.1157 · Cited by 1,123
Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis
Goldberg, I. J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37569-6 · Cited by 1,010
Cited by
Items 201–300 of 972
Chen, S., Okahara, F., Osaki, N., & Shimotoyodome, A. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00418.2014 · Cited by 88
“Genetic ablation of GIPR attenuates obesity induced by a high-fat diet and further improves insulin sensitivity in mice (20).”
BackgroundKirino, Y., Sato, Y., Kamimoto, T., Kawazoe, K., Minakuchi, K., & Nakahori, Y. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0424 · Cited by 91
“Recent studies of obesity have proposed that GIP, a substrate of DPP4, plays an important role in lipid abnormality since GIP is a key element linking overnutrition to obesity through increased nutrient uptake and triglyceride accumulation in adipocytes (Miyawaki et al. 2002, McClean et al. 2007).”
BackgroundFinan, B., Clemmensen, C., & Müller, T. D. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.003 · Cited by 88
Buhmann, H., le Roux, C. W., & Bueter, M. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.003 · Cited by 102
“However, GIP knockout animals display increased energy expenditure and both hormones have common actions on islet b cells, acting through related but structurally distinct receptors [75,98].”
BackgroundSparre-Ulrich, A. H., Gabe, M. N., Gasbjerg, L. S., Christiansen, C. B., Svendsen, B., Hartmann, B., Holst, J. J., & Rosenkilde, M. M. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.02.012 · Cited by 81
Self-citationA novel GIP receptor splice variant influences GIP sensitivity of pancreatic β-cells in obese mice
Harada, N., Yamada, Y., Tsukiyama, K., Yamada, C., Nakamura, Y., Mukai, E., Hamasaki, A., Liu, X., Toyoda, K., Seino, Y., et al. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00358.2007 · Cited by 85
“GIP is secreted from the K cells of the duodenum and proximal jejunum upon meal ingestion and binds to the GIP receptor (GIPR) on the surface of pancreatic -cells, adipose tissues, and osteoblasts to stimulate insulin secretion (21), fat accumulation (20), and bone formation (30) by increasing the level of intracellul…”
BackgroundSelf-citationGut Hormones and Energy Balance, The Future for Obesity Therapy?
Meiliana, A., & Wijaya, A. (2009) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v1i3.99 · Cited by 79
Zambrowicz, B., Ding, Z., Ogbaa, I., Frazier, K., Banks, P. L., Turnage, A., Freiman, J. P., Smith, M. G., Ruff, D. A., Sands, A., et al. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.01.010 · Cited by 84
Cholecystokinin Knockout Mice Are Resistant to High-Fat Diet-Induced Obesity
Lo, C., King, A., Samuelson, L. C., Kindel, T. L., Rider, T., Jandacek, R. J., Raybould, H. E., Woods, S. C., & Tso, P. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.044 · Cited by 78
Thondam, S. K., Cuthbertson, D. J., & Wilding, J. P. H. (2020) · Peptides · doi:10.1016/j.peptides.2019.170208 · Cited by 77
The incretin/glucagon system as a target for pharmacotherapy of obesity
Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews · doi:10.1111/obr.13372 · Cited by 77
“Mice lacking the GIPR are protected from diet-induced obesity, and crossing of GIPR-null mice with obese ob/ob mice reduces adiposity.(111,112) However, other studies have demonstrated a reduction in calorie intake and bodyweight after both central and peripheral administration of GIPR agonists.”
BackgroundSelf-citationGastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action
Zhou, H., Yamada, Y., Tsukiyama, K., Miyawaki, K., Hosokawa, M., Nagashima, K., Toyoda, K., Naitoh, R., Mizunoya, W., Fushiki, T., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.164 · Cited by 82
Self-citationGlucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide
Meier, J. J., & Nauck, M. A. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.08.007 · Cited by 82
Girard, J. R. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2008.09.001 · Cited by 85
Moffett, R. C., Vasu, S., Thorens, B., Drucker, D. J., & Flatt, P. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096863 · Cited by 75
“Others have reported normal or slightly elevated circulating GIP concentrations [52].”
BackgroundWhat is GLP-1 really doing in obesity?
Hira, T., Pinyo, J., & Hara, H. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.09.003 · Cited by 74
High glycemic index metabolic damage – a pivotal role of GIP and GLP-1
Pfeiffer, A. F. H., & Keyhani-Nejad, F. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.03.003 · Cited by 74
“GIPR / mice have an increased metabolic rate and are more active than control mice on a high-fat diet [55] or on high-GI diets [56], which supports central sites of action regulating physical activity [52].”
InfluentialSchmitt, C., Portron, A., Jadidi, S., Sarkar, N., & DiMarchi, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13024 · Cited by 74
The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity
Fukuda, M. (2021) · Diabetes · doi:10.2337/dbi21-0001 · Cited by 80
“Although favorable data to support this model accumulated for many years, direct evidence supporting a role for GIP as an obesogenic signal initially came from a seminal study by Seino and colleagues (5).”
BackgroundInfluentialWice, B. M., Wang, S., Crimmins, D. L., Diggs‐Andrews, K. A., Althage, M. C., Ford, E. L., Tran, H. D., Ohlendorf, M. F., Griest, T. A., Wang, Q., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.129304 · Cited by 77
Recent Updates on Obesity Treatments: Available Drugs and Future Directions
Dragano, N. R. V., Fernø, J., Diéguez, C., López, M., & Milbank, E. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.04.034 · Cited by 84
Physiological roles of the GIP receptor in murine brown adipose tissue
Beaudry, J. L., Kaur, K. D., Varin, E. M., Baggio, L. L., Cao, X., Mulvihill, E. E., Bates, H. E., Campbell, J. E., & Drucker, D. J. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.08.006 · Cited by 76
“Indeed, these findings have been achieved with a broad number of experimental approaches, including genetic inactivation of the GIP receptor (Gipr) [8], disruption of the Gip gene in mice [9], as well as GIPR blockade using receptor antagonists, or immunoneutralization of the GIP peptide in mice, rats, and non-human p…”
BackgroundInfluentialIncretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Michałowska, J., Miller-Kasprzak, E., & Bogdański, P. (2021) · Nutrients · doi:10.3390/nu13020351 · Cited by 68
“There was no significant genotype effect on changes in fasting glucose, insulin and HOMA-IR in the HFD group [172].”
BackgroundInfluentialSt‐Pierre, P., Pilon, G., Dumais, V., Dion, C., Dubois, M.-J., Dubé, P., Desjardins, Y., & Marette, A. (2014) · Journal of Functional Foods · doi:10.1016/j.jff.2014.10.001 · Cited by 80
Cluny, N. L., Eller, L. K., Keenan, C. M., Reimer, R. A., & Sharkey, K. A. (2015) · Obesity · doi:10.1002/oby.21017 · Cited by 72
“Antagonism of GIP receptor has been shown in animal models to prevent or reverse obesity and reduce hepatic and muscle lipid stores (27).”
BackgroundNarita, T., Yokoyama, H., Yamashita, R., Sato, T. K., Hosoba, M., Morii, T., Fujita, H., Tsukiyama, K., & Yamada, Y. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01526.x · Cited by 72
“In animal experiments of excess nutrient intake, reducing the GIP signal in a physiological level results in improvement of obesity, insulin resistance and glucose tolerance accompanied with prevention of fat accumulation into adipocytes and high energy expenditure, [1].”
BackgroundSelf-citationThe Role of Gastrointestinal Hormones in Hepatic Lipid Metabolism
Mells, J. E., & Anania, F. A. (2013) · Seminars in Liver Disease · doi:10.1055/s-0033-1358527 · Cited by 75
“23,73,76,79,82 However, several recent studies raise more questions concerning the benefits of pursuing GIP therapeutics.”
BackgroundThondam, S. K., Daousi, C., Wilding, J. P. H., Holst, J. J., Ameen, G. I., Yang, C., Whitmore, C., Mora, S., & Cuthbertson, D. J. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00347.2016 · Cited by 71
“The majority of the animal studies have shown that GIP potentiates the role of insulin in regulation of LPL and NEFA incorporation into adipose tissue (9, 15, 27, 31).”
Self-citationThe Regulation of Peripheral Metabolism by Gut-Derived Hormones
Sun, E. W. L., Martin, A. M., Young, R. L., & Keating, D. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00754 · Cited by 71
“Elevated GIP levels and duodenal K cell hyperplasia (62) have also been reported in HFD-treated mice, while Gipr deficiency protects mice from HFD-, leptin deficiency- or ovariectomy-induced weight gain (63, 64).”
BackgroundHolst, J. J., Albrechtsen, N. J. W., ROSENKILDE, M. M., & Deacon, C. F. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180013 · Cited by 77
Self-citationLavine, J. A., Raess, P. W., Stapleton, D. S., Rabaglia, M. E., Suhonen, J. I., Schueler, K. L., Koltes, J. E., Dawson, J., Yandell, B. S., Samuelson, L. C., et al. (2010) · Endocrinology · doi:10.1210/en.2010-0233 · Cited by 73
Murase, T., Yokoi, Y., Misawa, K., Ominami, H., Suzuki, Y., Shibuya, Y., & Hase, T. (2011) · British Journal Of Nutrition · doi:10.1017/s0007114511005083 · Cited by 79
“These studies suggest an important role of GIP in the regulation of fatty acid metabolism and fat deposition, and its physiological significance is emphasised by the fact that GIP receptor knockout mice fed a high-fat diet are obesity resistant (37) .”
Mechanisms of Disease: the role of gastrointestinal hormones in appetite and obesity
Vincent, R. P., Ashrafian, H., & le Roux, C. W. (2008) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep1118 · Cited by 76
“GIP-receptor knockout mice have reduced adipocyte mass, whilst also demonstrating resistance to diet-induced obesity despite being given a high-fat diet”
BackgroundGIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9
Mantelmacher, F. D., Zvibel, I., Cohen, K., Epshtein, A., Pasmanik-Chor, M., Vogl, T., Kuperman, Y., Weiss, S., Drucker, D. J., Varol, C., et al. (2018) · Nature Metabolism · doi:10.1038/s42255-018-0001-z · Cited by 70
Giezenaar, C., Hutchison, A. T., Luscombe‐Marsh, N. D., Chapman, I. M., Horowitz, M., & Soenen, S. (2017) · Nutrients · doi:10.3390/nu10010002 · Cited by 73
“Although the effect of GIP on human appetite and food intake, if any, is not clear, there is limited animal evidence to suggest it may act to stimulate food intake; GIP receptor-deficient mice are resistant to diet-induced obesity [26].”
BackgroundGIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue
Campbell, J. E., Beaudry, J. L., Svendsen, B., Baggio, L. L., Gordon, A. N., Ussher, J. R., Wong, C. K., Gribble, F. M., D’Alessio, D. A., Reimann, F., et al. (2022) · Diabetes · doi:10.2337/db21-1166 · Cited by 74
Inhibition of GIP signaling modulates adiponectin levels under high-fat diet in mice
Naitoh, R., Miyawaki, K., Harada, N., Mizunoya, W., Toyoda, K., Fushiki, T., Yamada, Y., Seino, Y., & Inagaki, N. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.08.052 · Cited by 71
“Energy expenditure was evaluated by measuring respiratory quotient and oxygen consumption by indirect calorimetry every 13 min for 24 h in mice under the fed condition, as described previously [8,9,12].”
BackgroundMethodInfluentialSelf-citationPyra, K. A., Saha, D. C., & Reimer, R. A. (2012) · Journal of Nutrition · doi:10.3945/jn.111.147132 · Cited by 73
“GIP receptor knockout(2/2) mice exhibit increased energy expenditure and are resistant to obesity and insulin resistance when fed a high-fat diet (34).”
BackgroundS100 proteins in obesity: liaisons dangereuses
Riuzzi, F., Chiappalupi, S., Arcuri, C., Giambanco, I., Sorci, G., & Donato, R. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03257-4 · Cited by 77
Flatt, P. R. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02455.x · Cited by 68
GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women
Rudovich, N. N., Kaiser, S., Engeli, S., Osterhoff, M. A., Gögebakan, Ö., Blüher, M., & Pfeiffer, A. F. H. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.02.006 · Cited by 74
Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology
Brandt, S. J., Müller, T. D., DiMarchi, R. D., Tschöp, M., & Stemmer, K. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12837 · Cited by 71
Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170174 · Cited by 67
Pharmacological antagonism of the incretin system protects against diet-induced obesity
Svendsen, B., Capozzi, M. E., Nui, J., Hannou, S. A., Finan, B., Naylor, J., Ravn, P., D'Alessio, D. A., & Campbell, J. E. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.11.018 · Cited by 67
Role of MGAT2 and DGAT1 in the release of gut peptides after triglyceride ingestion
Okawa, M., Fujii, K., Ohbuchi, K., Okumoto, M., Aragane, K., Sato, H., Tamai, Y., Seo, T., Itoh, Y., & Yoshimoto, R. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.08.167 · Cited by 68
Peripheral signalling involved in energy homeostasis control
Lancha, A., Frühbeck, G., & Gómez‐Ambrosi, J. (2012) · Nutrition Research Reviews · doi:10.1017/s0954422412000145 · Cited by 74
“cant increase in energy expenditure, protecting from highfat diet-induced obesity and insulin resistance((278,279,281)).”
BackgroundGastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice
Boylan, M. O., Glazebrook, P. A., Tatalovic, M., & Wolfe, M. M. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00345.2015 · Cited by 65
“Disruption of GIP signaling by genetic deletion of the GIP or GIPR genes (22, 27) by targeted ablation of GIP-producing K-cells (1), by the administration of GIP derivatives that act as competitive antagonists (8), or by vaccination (7) results in less efficient nutrient storage in mice fed a high-fat diet (HFD).”
BackgroundMethodInfluentialThe Role of GIP in the Regulation of GLP-1 Satiety and Nausea
Hayes, M. R., Borner, T., & Jonghe, B. C. D. (2021) · Diabetes · doi:10.2337/dbi21-0004 · Cited by 70
“, GLP-1(7-36)], this compound was resistant to enzymatic degradation by dipeptidyl peptidase IV.”
BackgroundGault, V. A., Porter, D., Irwin, N., & Flatt, P. R. (2011) · Journal of Endocrinology · doi:10.1530/joe-10-0419 · Cited by 65
“GIP receptor knockout mice exhibit a significant reduction of respiratory quotient during the light phase, but in agreement with the current study, modulation of GIP receptor signalling did not evoke changes in oxygen consumption (Miyawaki et al. 2002).”
Shimotoyodome, A., Suzuki, J. S., Fukuoka, D., Tokimitsu, I., & Hase, T. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00468.2009 · Cited by 70
“Previous studies have shown that the inhibition of GIP signaling increases fat oxidation and prevents the onset of obesity and consequent insulin resistance induced by a high-fat diet (38).”
BackgroundDifferential processing of pro-glucose-dependent insulinotropic polypeptide in gut
Fujita, Y., Asadi, A., Yang, G. K., Kwok, Y. N., & Kieffer, T. J. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00024.2010 · Cited by 66
Møller, C. L., Vistisen, D., Færch, K., Johansen, N. B., Witte, D. R., Jonsson, A. E., Pedersen, O. B., Hansen, T. F., Lauritzen, T., Jørgensen, M. E., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3133 · Cited by 69
“GIP receptor (GIPR) knockout mice have reduced sc adipose tissue depots, improved insulin sensitivity, and seem to be resistant to diet-induced obesity (1, 12).”
BackgroundSelf-citationReimann, F., & Gribble, F. M. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12478 · Cited by 69
Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors
Suzuki, R., Brown, G. A., Christopher, J. A., Scully, C. C. G., & Congreve, M. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00835 · Cited by 64
Xie, C., Jones, K. L., Rayner, C. K., & Wu, T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090790 · Cited by 67
“Moreover, GIP exhibits numerous extra-glycaemic actions; blockade of GIP signalling in mice preferentially increases fat oxidation [90–92], reduces fat accumulation in adipocytes [90,92,93] and skeletal muscle [91,92], decreases triglyceride deposition in the liver [90,93], and prevents the development of obesity [90,…”
BackgroundWeaver, R. E., Donnelly, D., Wabitsch, M., Grant, P. J., & Balmforth, A. J. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.148 · Cited by 63
Martinou, E., Stefanova, I., Iosif, E., & Angelidi, A. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063339 · Cited by 69
“reported that GIPR-deficient mice had normal body weight when consuming a normal diet, and when challenged with a high-fat diet, they gained less weight and their insulin sensitivity was preserved [239].”
BackgroundAdipose tissue as source and target for novel therapies
Klein, J. C., Perwitz, N., Kraus, D., & Faßhauer, M. (2005) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2005.11.008 · Cited by 70
Regulation of Postprandial Blood Metabolic Variables by TEMPO-Oxidized Cellulose Nanofibers
Shimotoyodome, A., Suzuki, J. S., Kumamoto, Y., Hase, T., & Isogai, A. (2011) · Biomacromolecules · doi:10.1021/bm2010609 · Cited by 70
Bergmann, N. C., Gasbjerg, L. S., Heimbürger, S. M., Krogh, L. S. L., Dela, F., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0578 · Cited by 62
Self-citationObesity medications in development
Rebello, C. J., & Greenway, F. L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1705277 · Cited by 62
Shibue, K., Yamane, S., Harada, N., Hamasaki, A., Suzuki, K., Joo, E., Iwasaki, K., Nasteska, D., Harada, T., Hayashi, Y., et al. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00543.2014 · Cited by 62
“Given that FABP5 expressed in GIP-producing K cells is involved in fat-induced GIP secretion (38) and that FABP5 / mice are resistant to the progression of DIO (24), we hypothesized that FABP5 contributes to the development of DIO via GIP secretion.”
BackgroundInfluentialBastin, M., & Andréelli, F. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s191438 · Cited by 67
Gastrointestinal hormones and the regulation of β‐cell mass
Lavine, J. A., & Attie, A. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05802.x · Cited by 63
Speakman, J. R. (2013) · Human Heredity · doi:10.1159/000353585 · Cited by 68
Im, D. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.09.001 · Cited by 68
“receptor deletions are resistant to diet-induced obesity (Holst, 2013; Miyawaki et al., 2002).”
BackgroundGIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review
Mori, Y., Matsui, T., Hirano, T., & Yamagishi, S.-I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041509 · Cited by 60
Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances
Asmar, M., & Holst, J. J. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283339051 · Cited by 65
Self-citationMohammad, S., Ramos, L. S., Buck, J., Levin, L. R., Rubino, F., & McGraw, T. E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.289009 · Cited by 59
Kim, S.-J., Nian, C., & McIntosh, C. H. S. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m012203 · Cited by 58
Glucose‐dependent insulinotropic polypeptide signaling in pancreatic β‐cells and adipocytes
McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2012) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2012.00196.x · Cited by 64
“Miyawaki et al.(87) first showed that GIPR mice were resistant to obesity when fed a high-fat diet.”
BackgroundMeier, J. J., Gallwitz, B., & Nauck, M. A. (2003) · BioDrugs · doi:10.2165/00063030-200317020-00002 · Cited by 67
Molecular mechanisms underlying nutrient detection by incretin-secreting cells
Reimann, F. (2009) · International Dairy Journal · doi:10.1016/j.idairyj.2009.11.014 · Cited by 61
Kelly, K. R., Brooks, L. M., Solomon, T. P. J., Kashyap, S., O’Leary, V. B., & Kirwan, J. P. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00112.2009 · Cited by 59
“GIP is secreted from K cells in the small intestine, and increased secretion has been reported in obesity (15, 31, 39), impaired glucose tolerance (IGT) (39), and type 2 diabetes mellitus (15).”
BackgroundAsmar, M., Simonsen, L., Arngrim, N., Holst, J. J., Dela, F., & Bülow, J. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.73 · Cited by 57
Self-citationSonestedt, E., Lyssenko, V., Ericson, U., Gullberg, B., Wirfält, E., Groop, L., & Orho‐Melander, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2444 · Cited by 61
“Experiments with gipr knockout mice have shown that GIPR inhibition could be used not only as a treatment strategy of obesity and disturbances in metabolic-related traits but also for prevention, because the gipr / mice when fed a high-fat diet did not gain weight and exhibited normal insulin sensitivity compared with…”
BackgroundTheodorakis, M. J., Carlson, O. D., Muller, D. C., & Egan, J. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.7.1692 · Cited by 62
“In addition, studies have demonstrated an obligatory role for GIP signaling in the development of obesity (33), in accordance with earlier evidence indicating that obese subjects exhibit greater postchallenge GIP excursions compared with appropriately matched control subjects (34), thus further supporting its potentia…”
ResultDiscovery of a potent GIPR peptide antagonist that is effective in rodent and human systems
Yang, B., Gelfanov, V. M., El, K., Chen, A., Rohlfs, R., DuBois, B., Kruse Hansen, A. M., Perez-Tilve, D., Knerr, P. J., D'Alessio, D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101638 · Cited by 55
Zhou, Q., Lei, X., Fu, S., Liu, P., Long, C., Wang, Y., Li, Z., Xie, Q., & Chen, Q. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01198-4 · Cited by 55
“…is implicated in adipose tissue mass and metabolism by regulating glucose uptake [41], lipolysis [42], and the activity of lipoprotein lipases [43, 44], some of which suggest the adipogenic effect of GIP with studies indicating GIPR knockout mice and chronic elevation of serum GIP levels in a…”
BackgroundIrwin, N., Gault, V. A., & Flatt, P. R. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.513381 · Cited by 57
“For instance, genetic knockout of the GIP receptor in normal or ob/ob mice fed a high-fat diet protects against obesity and related metabolic abnormalities [69,70].”
BackgroundPancreatic and Extrapancreatic Effects of Gastric Inhibitory Polypeptide
Yamada, Y., Miyawaki, K., Tsukiyama, K., Harada, N., Yamada, C., & Seino, Y. (2006) · Diabetes · doi:10.2337/db06-s011 · Cited by 55
“gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide”
BackgroundMethodSelf-citationIncretin actions beyond the pancreas: lessons from knockout mice
Yabe, D., & Seino, Y. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.013 · Cited by 57
“GIPR-deficient mice demonstrated higher energy expenditure with reduced oxygen consumption and respiratory quotient in the light phase, the latter indicating that fats are preferentially used as energy source [51].”
BackgroundInfluentialSelf-citationGIP analogues and the treatment of obesity-diabetes
Bailey, C. J. (2019) · Peptides · doi:10.1016/j.peptides.2019.170202 · Cited by 58
Novel Therapeutical Approaches to Managing Atherosclerotic Risk
Giglio, R. V., Stoian, A. P., Al‐Rasadi, K., Banach, M., Patti, A. M., Ciaccio, M., Rizvi, A. A., & Rizzo, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094633 · Cited by 57
Patterson, J. T., Ottaway, N., Gelfanov, V. M., Smiley, D. L., Pérez–Tilve, D., Pfluger, P. T., Tschöp, M. H., & DiMarchi, R. D. (2010) · ACS Chemical Biology · doi:10.1021/cb1002015 · Cited by 59
Moritoh, Y., Takeuchi, K., & Hazama, M. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.148056 · Cited by 60
“GIP plays a more important role in maintaining body weight than GLP-1 in obesity (Miyawaki et al., 2002; Flatt, 2008).”
BackgroundNie, Y., Ma, R. C., Chan, J. C. N., Xu, H., & Xu, G. (2012) · The FASEB Journal · doi:10.1096/fj.11-196782 · Cited by 53
“that blockade of GIP in mice led to resistance to diet-induced obesity and ameliorated insulin resistance (24, 25).”
BackgroundTirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence
Corrao, S., Pollicino, C., Maggio, D., Torres, A., & Argano, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1402583 · Cited by 62
“However, in a transgenic mouse model, persistently high GIP levels resulted in improvement of b -cell function, promote insulin sensitivity and gene transcription, glucose tolerance, and reduction in weight gain (15).”
BackgroundWhat model organisms and interactomics can reveal about the genetics of human obesity
Williams, M. J., Almén, M. S., Fredriksson, R., & Schiöth, H. B. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1022-5 · Cited by 57
“This observation confirmed that GIPR signalling is an essential component of the adipocyte response to chronic nutritional excess [27].”
BackgroundAOYAMA, E., WATARI, I., PODYMA-INOUE, K. A., YANAGISHITA, M., & ONO, T. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1787 · Cited by 52
“Several studies have also demonstrated that GIP mediates lipogenesis in adipocytes (6) and bone remodeling (7).”
Jepeal, L. I., Fujitani, Y., Boylan, M. O., Wilson, C. N., Wright, C. V. E., & Wolfe, M. M. (2004) · Endocrinology · doi:10.1210/en.2004-0223 · Cited by 58
GIP or not GIP? That is the question
Kieffer, T. J. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00031-2 · Cited by 56
Kodra, J. T., Jørgensen, A. S., Andersen, B., Behrens, C., Brand, C. L., Christensen, I. T., Guldbrandt, M., Jeppesen, C. B., Knudsen, L. B., Madsen, P., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7015599 · Cited by 52
GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells
Lima, N. D. S., Cabaleiro, A., Nóvoa, E., Riobello, C., Knerr, P. J., He, Y., Esquinas-Román, E. M., González‐García, I., Prévot, V., Schwaninger, M., et al. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05507-6 · Cited by 61
“…are presented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001, using a one-way ANOVA followed by a Bonferroni’s multiple comparison test While Gipr was not found in the liver of rodents [45], GIP enhances lipid deposition in liver and inhibition of GIP signal prevents this process [13, 30, 33].”
InfluentialCeddia, R. P., & Collins, S. (2020) · Clinical Science · doi:10.1042/cs20190579 · Cited by 52
Isken, F., Pfeiffer, A. F. H., Nogueiras, R., Osterhoff, M. A., Ristow, M., Thorens, B., Tschöp, M. H., & Weickert, M. O. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00008.2008 · Cited by 53
“The decreased food intake in OVX Gipr / mice is an unexpected and important novel result because previous studies (19) have shown that there was no significant difference in food intake between WT and Gipr / mice.”
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2192865 · Cited by 54
“Additionally, GIPR KO mice were reported to be resistant to the adipogenic effects of a high fat diet [113], but this is also true for GLP-1 R KO mice [114].”
BackgroundYamane, T., Kozuka, M., Konda, D., Nakano, Y., Nakagaki, T., Ohkubo, I., & Ariga, H. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.02.004 · Cited by 50
“fat is also induced by GIP in adipose tissues [19].”
BackgroundInhibition of dipeptidyl peptidase IV activity as a therapy of Type 2 diabetes
Green, B. D., Flatt, P. R., & Bailey, C. J. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.3.525 · Cited by 53
“Key actions, shown in Table 1, include the stimulation of insulin release from the pancreas [2], reduction of hepatic insulin clearance [3] and insulin-like effects on skeletal muscle [4-6], liver [7] and adipose tissue [8-11], which serve to promote glucose uptake and metabolism.”
BackgroundSamms, R. J., Sloop, K. W., Gribble, F. M., Reimann, F., & Adriaenssens, A. E. (2021) · Diabetes · doi:10.2337/dbi21-0002 · Cited by 49
“In addition, GIP is implicated in postprandial lipid metabolism (12), a phenomenon that has contributed to the hypothesis that GIP could promote obesity (14).”
Background
Metadata
- Authors
- Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., Hiai, H., Mizunoya, W., Fushiki, T., Holst, J. J., Makino, M., Tashita, A., Kobara, Y., Tsubamoto, Y., Jinnouchi, T., Jomori, T., & Seino, Y.
- Affiliations
- Kyoto University (JP)
- University of Copenhagen (DK)
- Sanwa Kagaku Kenkyusho Co., Ltd. (Japan) (JP)
- Corresponding author
- Seino, Yutaka
- Venue
- Nature Medicine
- Published
- 2002-06-17
- Volume
- 8
- Issue
- 7
- Pages
- 738-742
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2102392334
- Cited by
- 963
- References
- 24
- Citations by year
- 2026: 34 · 2025: 43 · 2024: 64 · 2023: 45 · 2022: 38 · 2021: 39 · 2020: 37 · 2019: 66 · 2018: 39 · 2017: 45 · 2016: 38 · 2015: 42 · 2014: 44 · 2013: 38 · 2012: 38
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor, obesity, insulin resistance, high-fat diet, adiposity, respiratory quotient, fat oxidation, anti-obesity drugs, overnutrition
- MeSH terms
- Adipose Tissue, Animals, Body Weight, Crosses, Genetic, Dietary Fats, Gastric Inhibitory Polypeptide, Obesity, Receptors, Gastrointestinal Hormone, Signal Transduction, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.